# A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

> **NCT00269893** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 2038 (actual)

## Conditions studied

- Angina, Unstable
- Angioplasty, Transluminal, Percutaneous Coronary

## Interventions

- **DRUG:** Abciximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00269893
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-11
- **Primary completion:** 1992-11
- **Final completion:** 1992-11
- **Target enrollment:** 2038 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269893, "A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00269893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*